Journey Medical Corporation
- Marktkapitalisierung
- $204.1M
- Volumen
- 168K
- Nächster Ergebnistermin
- Nov 11, 2026
Journey Medical Corporation (DERM) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $15.96M | n/a | +21.48% |
| EPS | -$0.01 | +$0.01 | +93.75% |
Kennzahlen
- Geld
- 5.17
- Marktkapitalisierung
- 204M
- Umsatz (TTM)
- 68.2M
- Nettogewinn (TTM)
- -6.1M
- 1.10
- -0.22
- n/a
- -120.5
- KBV (TTM)
- 6.23
- KUV (TTM)
- 2.99
- Termin Quartalszahlen
- Nov 11, 2026
- Brief
- 9.24
- Volumen
- 167,997
- Ø Vol. (20D)
- 242,456
- Eröffnung
- 7.18
- Vortagesschluss
- 7.09
- Tagesspanne
- 7.06 - 7.41
- 52-Wk Range
- 4.31 - 9.55
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Journey Medical Corporation
Profil ansehen →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.